You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The firm initially plans to apply the method, which measures the size of specific macrophages in blood, to predict lung cancer immunotherapy response.
At the American Society of Clinical Oncology's virtual meeting, investigators presented two new studies of BluePrint classification patterns.
In a retrospective study, investigators saw a survival benefit among head and neck cancer patients with high TMB treated with checkpoint inhibitors.
The field is collecting evidence supporting genomics-guided care but experts are still awaiting prospective data and grappling with other challenges.
The firm presented a poster at ASCO suggesting that its StemPrintER platform outperforms Exact Science's Oncotype Dx for predicting breast cancer recurrence.
Two studies presented at ASCO's virtual annual meeting demonstrated the clinical utility of germline findings in guiding treatment decisions in cancer.
New data shows that the test could eventually be useful in helping younger women avoid chemotherapy in the neoadjuvant setting.
Breast cancer risk in carriers of pathogenic CHEK2 variants may be classified as low, moderate, or high by adding in polygenic risk score and family history data.
The INFORM study echoed the 2019 interim results from the NCI Pediatric MATCH trial, which found that 24 percent of participants were eligible for targeted treatment.
In the near term, the firm will launch a laboratory-developed, late-stage lung cancer assay out of its lab in Palo Alto.